NASDAQ:TXMD - TherapeuticsMD Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$5.65 -0.08 (-1.40 %)
(As of 02/18/2019 04:00 PM ET)
Previous Close$5.73
Today's Range$5.63 - $5.98
52-Week Range$3.51 - $7.66
Volume2.63 million shs
Average Volume2.79 million shs
Market Capitalization$1.34 billion
P/E Ratio-15.27
Dividend YieldN/A
Beta2.06
TherapeuticsMD, Inc. operates as a women's health care product company. Its pipeline of hormone therapy drug candidates include TX-001HR, a combination of estradiol and progesterone drug candidate under clinical trials for the treatment of moderate to severe vasomotor symptoms due to menopause; TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil; and TX-004HR, an applicator-free vaginal estradiol softgel drug candidate for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy in post-menopausal women with vaginal linings that do not receive enough estrogen. The company also manufactures and distributes branded and generic prescription prenatal vitamins under the vitaMedMD and BocaGreenMD brands. It markets its products primarily through a direct national sales force to health care providers in the OB/GYN market space. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.

Receive TXMD News and Ratings via Email

Sign-up to receive the latest news and ratings for TXMD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TXMD
Previous SymbolNYSEMKT:TXMD
CUSIPN/A
Phone561-961-1900

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$16.78 million
Book Value$0.60 per share

Profitability

Net Income$-76,920,000.00
Net Margins-757.59%

Miscellaneous

Employees173
Market Cap$1.34 billion
OptionableOptionable

TherapeuticsMD (NASDAQ:TXMD) Frequently Asked Questions

What is TherapeuticsMD's stock symbol?

TherapeuticsMD trades on the NASDAQ under the ticker symbol "TXMD."

How were TherapeuticsMD's earnings last quarter?

TherapeuticsMD Inc (NASDAQ:TXMD) issued its earnings results on Thursday, May, 3rd. The company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.10) by $0.01. The firm earned $3.77 million during the quarter, compared to the consensus estimate of $4.18 million. TherapeuticsMD had a negative return on equity of 102.15% and a negative net margin of 757.59%. The firm's revenue for the quarter was down 5.4% compared to the same quarter last year. During the same period last year, the business earned ($0.11) earnings per share. View TherapeuticsMD's Earnings History.

When is TherapeuticsMD's next earnings date?

TherapeuticsMD is scheduled to release their next quarterly earnings announcement on Thursday, February 21st 2019. View Earnings Estimates for TherapeuticsMD.

How can I listen to TherapeuticsMD's earnings call?

TherapeuticsMD will be holding an earnings conference call on Thursday, February 21st at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link or dial in at 8666659531.

What price target have analysts set for TXMD?

4 brokerages have issued 12-month price objectives for TherapeuticsMD's stock. Their predictions range from $11.00 to $27.00. On average, they expect TherapeuticsMD's stock price to reach $17.3333 in the next twelve months. This suggests a possible upside of 206.8% from the stock's current price. View Analyst Price Targets for TherapeuticsMD.

What is the consensus analysts' recommendation for TherapeuticsMD?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TherapeuticsMD in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for TherapeuticsMD.

What are Wall Street analysts saying about TherapeuticsMD stock?

Here are some recent quotes from research analysts about TherapeuticsMD stock:
  • 1. Cantor Fitzgerald analysts commented, "We reiterate our OW rating. The execution behind the launches of Annovera is underappreciated, in our view, and we think peak sales could exceed modest expectations for three drugs that target large unmet needs. Valuation Summary We use a blend of EV/EBITDA and DCF analysis to arrive at our 12-month PT of $27. The Disclosure Section may be found on pages 3 – 4.Valuation We use a blend of EV/EBITDA and DCF analysis to arrive at our 12-month PT of $27." (1/21/2019)
  • 2. According to Zacks Investment Research, "TherapeuticsMD, Inc. is a specialty pharmaceutical company focused on creating branded prescription, generic prescription and over-the-counter products targeted exclusively for women. It is developing three advanced hormone replacement products designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies. TherapeuticsMD, Inc. is based in Boca Raton, Florida. " (11/2/2018)

Has TherapeuticsMD been receiving favorable news coverage?

News articles about TXMD stock have been trending positive on Monday, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. TherapeuticsMD earned a coverage optimism score of 2.3 on InfoTrie's scale. They also gave news articles about the company a news buzz of 6.0 out of 10, indicating that recent press coverage is somewhat likely to have an impact on the stock's share price in the immediate future.

Are investors shorting TherapeuticsMD?

TherapeuticsMD saw a increase in short interest in the month of January. As of January 31st, there was short interest totalling 70,507,377 shares, an increase of 1.3% from the January 15th total of 69,627,712 shares. Based on an average daily trading volume, of 2,309,042 shares, the days-to-cover ratio is currently 30.5 days. Currently, 36.1% of the shares of the stock are short sold. View TherapeuticsMD's Current Options Chain.

Who are some of TherapeuticsMD's key competitors?

Who are TherapeuticsMD's key executives?

TherapeuticsMD's management team includes the folowing people:
  • Mr. Robert G. Finizio, Co-Founder, CEO & Director (Age 47)
  • Mr. John C. K. Milligan IV, Pres, Sec. & Director (Age 56)
  • Dr. Brian A. Bernick, Co-Founder, Chief Clinical Officer & Director (Age 50)
  • Mr. Daniel Alan Cartwright, CFO & Treasurer (Age 60)
  • Mr. Mitchell L. Krassan, Exec. VP & Chief Strategy Officer (Age 52)

Who are TherapeuticsMD's major shareholders?

TherapeuticsMD's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Bank of New York Mellon Corp (12.82%), BlackRock Inc. (7.02%), Millennium Management LLC (1.20%), Stifel Financial Corp (1.02%), Northern Trust Corp (0.96%) and Geode Capital Management LLC (0.93%). Company insiders that own TherapeuticsMD stock include Brian Bernick, Daniel A Cartwright, John CK Iv Milligan, Robert G Finizio and Tommy G Thompson. View Institutional Ownership Trends for TherapeuticsMD.

Which institutional investors are selling TherapeuticsMD stock?

TXMD stock was sold by a variety of institutional investors in the last quarter, including TD Asset Management Inc., Raymond James & Associates, Bank of Montreal Can, MetLife Investment Advisors LLC, Natixis Advisors L.P., First Trust Advisors LP, Mengis Capital Management Inc. and Northern Trust Corp. Company insiders that have sold TherapeuticsMD company stock in the last year include Brian Bernick, Daniel A Cartwright, John CK Iv Milligan and Robert G Finizio. View Insider Buying and Selling for TherapeuticsMD.

Which institutional investors are buying TherapeuticsMD stock?

TXMD stock was purchased by a variety of institutional investors in the last quarter, including Millennium Management LLC, Frontier Capital Management Co. LLC, BlackRock Inc., Stifel Financial Corp, 1492 Capital Management LLC, Public Employees Retirement Association of Colorado, Bank of New York Mellon Corp and Geode Capital Management LLC. View Insider Buying and Selling for TherapeuticsMD.

How do I buy shares of TherapeuticsMD?

Shares of TXMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is TherapeuticsMD's stock price today?

One share of TXMD stock can currently be purchased for approximately $5.65.

How big of a company is TherapeuticsMD?

TherapeuticsMD has a market capitalization of $1.34 billion and generates $16.78 million in revenue each year. The company earns $-76,920,000.00 in net income (profit) each year or ($0.37) on an earnings per share basis. TherapeuticsMD employs 173 workers across the globe.

What is TherapeuticsMD's official website?

The official website for TherapeuticsMD is http://www.therapeuticsmd.com.

How can I contact TherapeuticsMD?

TherapeuticsMD's mailing address is 6800 BROKEN SOUND PARKWAY NW, BOCA RATON FL, 33487. The company can be reached via phone at 561-961-1900 or via email at [email protected]


MarketBeat Community Rating for TherapeuticsMD (NASDAQ TXMD)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  276 (Vote Outperform)
Underperform Votes:  221 (Vote Underperform)
Total Votes:  497
MarketBeat's community ratings are surveys of what our community members think about TherapeuticsMD and other stocks. Vote "Outperform" if you believe TXMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TXMD will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/18/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel